PLRX: Pliant Therapeutics Forvard P/E multiplikatori

pliantrx.com (PLRX) grafik logotipi

Pliant Therapeutics (PLRX) fibrozisga qarshi kurashish usullarini ishlab chiqadi, bunda patentlashdan keyingi yuqori daromadlilik foydaning keskin o'sishini ta'minlaydi. GURU.Markets platformasidagi emitentning forward P/E ko'rsatkichi ushbu tendentsiyani vizuallashtiradi, bunda 0.00 belgisi ushbu metrikani aks ettiradi. Bozor kapitalizatsiyasining o'sishi inhibitorlar portfelining kengayishi va B2B sherikliklariga bog'liq, ishlab chiqarishni autsorsing qilish risklari esa qat'iy muhandislik nazorati orqali yumshatiladi.

Pliant Therapeutics - PLRX Narxning kutilayotgan foydaga nisbati (davr: 04.07.2022 - 15.11.2026)

Pliant Therapeutics, Inc. (PLRX) - koʻrsatkichlar kesimi va moliyaviy hisobotlar

- aksiyalar qiymati va narxlar bo'yicha konsensus prognoz:
Fundamental baholash:PLRX Pliant Therapeutics Inc
pliantrx.com brendining mahsuloti

Prognoz qilinayotgan P/E ko'rsatkichi Pliant Therapeutics (PLRX) kompaniyasining bozor qiymatini keyingi 12 oy ichidagi kutilayotgan foyda bilan nisbatda aks ettiradi, bu esa investorlarga haddan tashqari ko'p to'lov qilish xavfi yoki fundamental aktivlarning yomonlashishini baholash imkonini beradi. Kompaniyaning joriy prognoz qilinayotgan P/E ko'rsatkichini tahlil qilib, bozor multiplikatorlarni R&D samaradorligi bilan solishtiradi, bunda asosiy bioximiklar va fibroz ekspertlarining saqlanib qolishi muvaffaqiyatli klinik sinovlar orqali kapitalizatsiya potentsialini tasdiqlaydi.

Pliant Therapeutics raqobatchilari tahlili

Kelajakdagi narxning foydaga nisbati Vertex Pharmaceuticals Inc. (VRTX)|Kelajakdagi narxning foydaga nisbati ALNY (Alnylam Inc.)|Forvard P/E multiplikatori INSM (insmed.com)|Kapitalizatsiyaning prognoz qilingan foydaga nisbati United Therapeutics Corporation (UTHR)|BMRN: Prognoz qilingan narxning foydaga nisbati|Narxning kutilayotgan foydaga nisbati BBIO|BGM: Forvard P/E multiplikatori|Prognoz qilingan narx-foyda nisbati Cogent Bio (COGT)|XERS (Xeris Biopharma Holdings) - Forvard P/E multiplikatori|Narxning kelajakdagi foydaga nisbati KROS (Keros Therapeutics, Inc.)|Prognoz qilingan narxning foydaga nisbati ARCT (Arcturus Therapeutics Holdings Inc.)|ETON (Eton Pharmaceuticals Inc) - Kelajakdagi narx-foyda multiplikatori|Kelajakdagi narxning foydaga nisbati Kamada KMDA|FULC (Fulcrum Tx) - Narxning kutilayotgan foydaga nisbati|Abeona Therapeutics Inc. - Forvard P/E multiplikatori|Kelajakdagi narx-foyda multiplikatori MREO (mereobiopharma.com)|Protalix BioTherapeutics, Inc. (PLX) - Kelajakdagi narxning foydaga nisbati|Applied Therapeutics Inc. (APLT) - Forvard P/E multiplikatori|Kelajakdagi narxning foydaga nisbati Rein Therapeutics, Inc.|GELS: Kelajakdagi narx-foyda multiplikatori|Kelajakdagi narxning foydaga nisbati Aytu BioPharma Inc (AYTU)|Prognoz qilingan narxning foydaga nisbati Chemomab Therapeutics Ltd. CMMB|Forvard P/E multiplikatori SRXH (SRx Health Solutions Inc)|Forvard P/E multiplikatori Polyrizon Ltd PLRZ|Aeterna Zentaris - Forvard P/E multiplikatori|Cyclo Therapeutics (CYTH) - Prognoz qilingan narxning foydaga nisbati|Inozyme Pharma, Inc. (INZY) - Kelajakdagi narxning foydaga nisbati|Prognoz qilingan narx-foyda nisbati reneopharma.com (RPHM)|Kelajakdagi narxning foydaga nisbati COSCIENS Biopharma Inc